PBAC's latest decision on Sevelamer: Recommended with restriction (2017). Considered for Hyperphosphataemia in patients undergoing dialysis for chronic kidney disease (adults aged 18 years and over with stage 4 and 5 CKD).
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Adults aged 18 years and over with stage 4 and 5 chronic kidney disease undergoing dialysis, with hyperphosphataemia not adequately controlled by calcium (serum phosphate >1.6 mmol/L or calcium × phosphate product >4), not using other non-calcium phosphate binding agents.
Therapy area
Endocrinology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Cost-minimisation
Key trials
GD3-163-201, SVCARB00205, GD3-199-301
Comparator
sevelamer hydrochloride
Economic model
Cost-minimisation
ICER note
Cost-minimisation submission; no ICER calculated. The submission proposed cost-neutrality based on price parity per milligram equivalence with sevelamer hydrochloride.